DOI: 10.11958/20252986
Research progress on the relationship between EGFR-TKI resistance and p53 mutation in non-small cell lung cancer
HUANG Zengyuan
FU Jing
ZHAO Ya
WANG Longhao
CANG Shundong
Abstract：The main reason for the failure of epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs)in the treatment of non-small cell lung cancer(NSCLC)is targeting drug resistance,and the main cause of drug resistance is the mutation of the tumor suppressor gene p53.How to prevent or reverse p53 mutations to solve the problem of EGFR-TKI resistance in advanced NSCLC has become a research hotspot in this field.This article summarizes the common mutation types of p53 and their related mechanisms affecting EGFR-TKI resistance,as well as how to intervene in p53 mutations to reverse EGFR-TKI resistance,and conducts an in-depth discussion on the relationship between EGFR-TKI resistance and p53 mutations in NSCLC patients.
Keywords：carcinomanon-small-cell lunggenesp53mutationEGFR-TKI
Publication Date：2026-03-15
Online Publishing Date：2026-03-26(First online date of this platform, not the publication date of the document)
Pages：4( 333-336 )